<DOC>
	<DOCNO>NCT00186628</DOCNO>
	<brief_summary>To determine Rituximab administer allogeneic transplantation decrease incidence chronic GvHD</brief_summary>
	<brief_title>Phase II Trial Prophylactic Rituximab Therapy Prevention CGVHD</brief_title>
	<detailed_description>To test prophylactic Rituximab give 35 patient 60-90 day allogeneic transplantation prevent chronic Graft-versus-Host Disease</detailed_description>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>( A ) Patients age great 17 less 76 . ( B ) CLL patient unmutated IgG VH gene status immediately eligible patient mutate IgG VH gene ( &gt; 2 % nucleotide change compare somatic sequence ) eligible consider appropriate HSCT physician . CLL patient complete remission benefit allogeneic HSCT , physicians encourage provide aggressive chemotherapy prior nonmyeloablative transplantation . ( C ) MCL patient BMT physician believe would benefit allogeneic HSCT . ( D ) Adequate renal ( Cr &lt; 2.4 mg/dl ) hepatic ( Bilirubin &lt; 3.0 mg/dl , AST &lt; 100 IU ) function . Patients lab result excess enrol approval PI . ( E ) Men woman reproductive potential must agree use acceptable method birth control treatment six month completion treatment . ( F ) All subject must provide write informed consent Donor Inclusion Criteria ( A ) Genotypically phenotypically HLAidentical . ( B ) Donor age &lt; 75 unless clear institutional P.I ( C ) Capable give write , informed consent . ( D ) Donor must consent PBSC mobilization GCSF apheresis ( A ) Patient age le 18 great 75 ( B ) Patient 9/10 10/10 HLA identical donor ( high resolution molecular genotyping HLA A , B , C DrB1 , DQ ) ( C ) Standard exclusion allogeneic transplantation include : i. Pregnancy lactation ii . Serious uncontrolled infection iii . HIV seropositivity iv . Hepatitis B C seropositivity v. Cardiac function : ejection fraction &lt; 40 % uncontrolled cardiac failure vi . Pulmonary : DLCO &lt; 50 % predict vii . Liver function abnormality : elevation bilirubin &gt; = 3 mg/dl and/or AST &gt; 100 viii . Renal : creatinine &gt; 2.4 ix . Karnofsky performance score &lt; = 60 % x . Patients poorly control hypertension ( SBP &gt; 150 DBP &gt; 90 repeatedly ) . ( D ) Known lifethreatening hypersensitivity Rituximab antiB cell antibody exclusion criterion . Previous Rituximab therapy neither require , exclusion criterion , carefully assess correlate outcome . ( E ) Inability comply allogeneic transplant treatment . ( F ) Uncontrolled CNS involvement disease Donor Exclusion Criteria ( A ) Identical twin ( B ) Any contraindication administration subcutaneous GCSF dose 16mg/kg/d five consecutive day ( C ) Serious medical psychological illness ( D ) Pregnant lactate female ( E ) Prior malignancy within precede five year , exception nonmelanoma skin cancer . ( F ) HIV seropositivity</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>